What is the Impact Factor of Current Cancer Drug Targets?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Current Cancer Drug Targets is 2.50, ranking in quartile Q3 of Web of Science (SCIE).

Is Current Cancer Drug Targets indexed in Web of Science or Scopus?

Yes, Current Cancer Drug Targets is indexed in Web of Science (SCIE, Q3 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.726 (Q2) and an H-index of 109.

Who publishes Current Cancer Drug Targets and what is the Article Processing Charge (APC)?

Current Cancer Drug Targets is published by Bentham Science Publishers B.V.. The estimated Article Processing Charge (APC) is approximately $3,120 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Current Cancer Drug Targets?

The official ISO-4 abbreviation of Current Cancer Drug Targets is "CURR. CANCER DRUG TARGETS". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q3Scopus Q2SCImago #7,884Hybrid

Current Cancer Drug Targets

Abbreviation (ISO):CURR. CANCER DRUG TARGETS

•

Identifier (ISSN):1568-0096(Print)/1873-5576(Online)

•

Publisher:Bentham Science Publishers B.V.

Official Website Submission Portal Compare

Clarivate IF (2026)

2.5↓ -1

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Current Cancer Drug Targets

WoS Q3

Annual Impact Factor Metric

Current (2026):2.5

Scopus SJR & RankScopus Q2

0.726

#7,884

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

109

109 papers with at least that number of citations each

WoS: SCIE / JCRQ3

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

70articles/year

8.03% Gold OA•42.65% Original Research

Aims & Scope

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Topics Covered (Recognized by AI)

Medicine94.4%Biology94%Genetics91.6%Internal medicine85.7%Chemistry80.4%Biochemistry77.6%Cancer research70.1%Cancer68.5%Gene49.5%Cell biology42.9%Immunology33.6%Pathology32.5%Apoptosis27.4%Pharmacology25.7%Oncology22.4%Signal transduction21.8%Organic chemistry20.8%Physics20.7%

Primary Research Areas

Medicine Oncology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

ONCOLOGY

Rank204/333

IndexSCIE

JCISCIE2026

ONCOLOGY

Rank224/333

IndexSCIE

Category	Index	Rank	Quartile
ONCOLOGY	JCRSCIE	204/333	Q3
ONCOLOGY	JCISCIE	224/333	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF2.5

Articles / Year108

Total Citations10

2025

IF3.5

Articles / Year125

Total Citations202

2024

IF2.3

Articles / Year143

Total Citations525

2023

IF3

Articles / Year96

Total Citations750

2022

IF2.907

Articles / Year105

Total Citations1,041

Year	Impact Factor	Articles / Year	Total Citations
2026	2.5	108	10
2025	3.5	125	202
2024	2.3	143	525
2023	3	96	750
2022	2.907	105	1,041
2021	3.428	71	767
2020	2.912	91	1,303
2019	2.72	53	1,184
2018	2.626	103	2,605
2017	—	103	3,047
2016	—	93	2,108
2015	—	98	2,164

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #7,884Scopus Q2SCImago Profile

Scopus Coverage:2001-2026

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q2

0.726

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

2.95

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,120 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations734

3-Year Documents243

Citable Documents238

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate44.3%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Drug DiscoveryQ2

PharmacologyQ2

Cancer ResearchQ3

OncologyQ3

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

4区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Current Cancer Drug Targets (abbr: CURR. CANCER DRUG TARGETS, ISSN: 1568-0096) is a peer-reviewed international scholarly journal in the field of Medicine, published by Bentham Science Publishers B.V. in Netherlands since 2001. The periodical holds a Journal Impact Factor (JIF) of 2.50, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.726 (Q2), an H-index of 109.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 70 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,120 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.